Establishment Of Nude Mouse Model Of MG63 Osteosarcoma And Experimental Study Of Cisplatin Sustained Release Implant For Osteosarcoma

Background Osteosarcoma(Osteosarcoma,OS)is the most common malignant tumor in the skeletal system,accounting for 20% of the primary malignant bone tumor.Nowadays,with the development and progress of medicine,the overall survival rate of osteosarcoma patients has increased,but the incidence of distant metastasis and limb amputation in osteosarcoma patients is still very high.Reduce the mass,kill small metastases undetectable by the naked eye,combined with later limb preservation and radiotherapy and chemotherapy.Traditional transformation Scientific therapy,mainly through the venous system input cisplatin,doxorubicin and other chemotherapeutic drugs.This method has many disadvantages.Long-term high-dose chemotherapy drugs can lead to serious complications related to veins.In addition,only some drugs reach the tumor site,resulting in poor chemotherapy effect.The toxic effects of systemic medication can cause serious damage to normal organs and tissues.At present,cisplatin is a commonly used chemotherapeutic drug for osteosarcoma,and its toxicity and drug resistance are greatly disadvantages.Local targeted therapy using degradable materials as cisplatin drug delivery not only improves bone and bone In addition,local targeted therapy is of great significance for the recurrence and metastasis of osteosarcoma.Objective A new cisplatin sustained release implant was developed and a nude mouse model of osteosarcoma was established to detect the effect of the implant on osteosarcoma.Methods We prepared cisplatin sustained release implants by mixing a certain proportion of cisplatin,polylactic acid-hydroxyacetic acid copolymer(PLGA),polyethylene glycol 4000(PEG-4000)using hot melt direct pressure method,using the high performance liquid chromatograph(HPLC)scanning electron microscope(SEM)was used to analyze the drug content,microscopic morphology,and the performance and characteristics of the implant were determined by in vitro degradation,in vitro and in vivo drug release experiments.additionally,we developed a human-derived osteosarcoma cell line MG-63 nude mouse model to analyze the antitumor efficacy of cisplatin sustained-release implants.Results We successfully prepared cisplatin sustained release implant.A series of tests showed that cisplatin molecules were uniformly distributed in the implant,with an average drug content of about 37.7%.The results of drug release experiments in vivo and in vitro showed that the initial release of the implant and the sustained and stable release of the implant could ensure the effective treatment concentration around the tumor.In addition,according to the experimental study of cisplatin sustained release agent implanted in nude mouse model of osteosarcoma,it is proved that the implant can effectively inhibit the growth of swelling and reduce the toxic effect on normal organs and tissues.Conclusions according to our study,cisplatin sustained-release implants can significantly inhibit tumor growth and reduce drug-related side effects in osteosarcoma MG63 nude mice.Therefore,we infer that cisplatin sustained-release implants are a new way to treat osteosarcoma.